CALDARET MONOHYDRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H16N2O3S.H2O
Molecular Weight	274.337
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.CC1=CC(=C(C=C1)N2CCNCC2)S(O)(=O)=O

InChI

InChIKey=ZRQKZWAOIRVBFD-UHFFFAOYSA-N

InChI=1S/C11H16N2O3S.H2O/c1-9-2-3-10(11(8-9)17(14,15)16)13-6-4-12-5-7-13;/h2-3,8,12H,4-7H2,1H3,(H,14,15,16);1H2

HIDE SMILES / InChI

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT00078013 | https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19970618&CC=EP&NR=0779283A1&KC=A1 | https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20030213&CC=WO&NR=03011296A1&KC=A1

Caldaret is intracardiac calcium (Ca2+) handling modulator whose cardioprotective actions are presumed to be due to inhibition of the NCX exchanger and increasing the uptake of Ca2+ via the sarcoplasmic reticulum (SR). Unfortunately, Caldaret failed to demonstrate efficacy in Phase II clinical trials as an adjunct to standard therapy with primary percutaneous coronary intervention patients diagnosed as having an acute myocardial infarction

Originator

Approval Year

PubMed

Title	Date	PubMed
Breast-feeding may reduce later blood pressure.	2004 Mar 16	15023898
Effect of caldaret on the incidence of severe left ventricular dysfunction in patients with ST-elevation myocardial infarction undergoing primary coronary intervention.	2009 Jan 1	19101220

Patents

Sample Use Guides

In Vivo Use Guide

4.5 mg/kg/48 hours

Route of Administration: Intravenous

Name

Type

Language

CALDARET MONOHYDRATE

Common Name

English

MCC-135

Common Name

English

BENZENESULFONIC ACID, 5-METHYL-2-(1-PIPERAZINYL)-, MONOHYDRATE

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID20431256